Supporting Individuals with Intellectual and Developmental Disability During the First 100 Days of the COVID-19 Outbreak in the U.S. BrightSpring Health Services Chief Medical Officer Dr. William Mills presents on BrightSpring's ongoing response to COVID-19 and how the organization is mitigating risks for our patients, clients, and team members.

1. COVID-19 RESPONSE - UPDATE
AUGUST 12, 2020

2.  Welcome
 Company Overview
 COVID-19 Update
 Q&A
 Summary and Next Steps
John.Mudgett@rescare.com
AGENDA

3. Behavioral Health
Neuro Therapies
(Rehab)
Specialty Drugs
Home Health Care
Home Infusion
Leading Provider of Diversified Home and
Community Health and Pharmacy Services
to Medically Complex Patient Populations
330,000+ patients served daily across 50 states
9,000+ clinical providers and pharmacists serving ~ 6,400+ facilities
Company Uniquely Provides a Full Spectrum of Services to High Cost and “Must-Serve” Seniors and Specialty
Clients / Patients with Significant Life-Long Chronic Health Needs
Skilled Nursing, Senior Living,
Hospital & Other LTC Pharmacy Services
Behavioral (I/DD) Pharmacy
Workforce Rehabilitation
COMPANY SNAPSHOT

4. LEGACY VALUE SYSTEM DRIVES STRONG COMPANY CULTURE
Mission, Vision and Values
“The leading provider of comprehensive home and
community based health services to complex populations”
“Making a difference in people’s lives and communities”
“Helping people live their best life”
VISION MISSION
LEGACY: Values and Core Behaviors
LEGACY Leadershipand ManagementSystem:
for FOCUSon the SuccessFactors of a Business
Over 20,000 peer-to-peerLEGACY recognitionsmade
to date across the company – recognizingcore behaviors in practice
11 DSPs won ANCOR’s “DSP of the Year” Award
Over 150 “Working Smart, Doing Good” Caregiver Profiles
New “Summit Award” and “Legacy of Care Award” Programs
S
Systems (Tools and Technology)
Leadership
(LEGACY Starts with Leadership)
F
First in
Quality
O
Operational
Excellence
C
Customer
Growth
People
U
YOU!
Training
Management Practices
Leadership:Be a Servant Leader
 Everyone is a leader. Establish purpose and coach to make others better.
Environment:People FocusedEnvironment
 Collaborate among a trusting team. Reward good performance.
Get Going:KnowYour Business
 Think. Plan. Act. Take action to set and hit goals.
Attitude:See thePossibilities
 Take a positive, can-do approach, because that is contagious.
Communication:Everyone in the Know
 Coordinate through communicating, so people know what’s going on.
You: Be an Example
 Stop and reflect. Set high standards, but note progress and the good.
L
E
G
A
C
Y
Over 20,000 peer-to-peer LEGACY recognitions made
to date across the company – recognizing core behaviors in practice
11 DSPs won ANCOR’s “DSP of the Year” Award
Over 300 “Working Smart, Doing Good” Caregiver Profiles
New “Summit Award” and “Legacy of Care Award” Programs

5. DIFFERENTIATED PLATFORM AND CAPABILITIES
Providing Pharmacy and Provider Services to the Highest Cost and Most Complex Populations
Seniors
Specialty
Populations
Pharmacy and Health Services Provider Company delivering daily non-clinical, daily pharmacy, and clinical
services and care management services – all of which are required to support complex populations
Daily Non-Clinical(ADL) Supports
Daily Medication Management
Clinicaland Care ManagementServices
Pharmacy
Solutions
Home and Community
Health Services Provider
&

6. QUALITY 1ST FRAMEWORK
Enablers Driving Quality
Quality 1st Framework
Culture and Auditing
 “LEGACY” and "STARS"
 Recognition programs
 Accreditation
 Ongoing/Targeted audits
 Site review frequency, checklist,
and data entry
Training
 Site Review Certification
 Position Specific Training
 Online Training; PMC Univ.
 Ongoing Education Series
 Ongoing Health Services Training Series
 Pharmacist, Nurse Consulting Services
Technology
 Site Review App
 Telecare; PERS
 EHRs; QuickMAR (Rx)
 ViewMasteRx
 RxAllow and
RxForecaster
Data Analytics
 Quality Review & Improvement
Committee
 Critical Incidents
 Best-In-Class Scores
 New Site Review Scores
 Risk tiering sites with a QAPI focus
 External survey and satisfaction results
Signature Programs
 You're Safe – I'm Safe
 Fall, Pneumonia Prevention
 Behavior Support
 Food Preparation
 Safe Home, Dementia Care
 RxNow, RxSentry
 TransitionRx, DischargeRx
Committed to continuous quality and safety improvement demonstrated by significant investments

7. QUALITY HIGHLIGHTS
Strong Clinical and Quality Measures Across All Businesses that Exceed National Averages
Neuro Therapies (Rehab)
 Outstanding Value and Clinical Improvement Results:
 40% - 70% reduction (53% combined average in Q3) in
percent of patients requiring 24 hour supervision
 45% - 75% (58% combined avg in Q3) increase in
percent of patients who can be left alone for 8 hours
 25% - 30% improvement in MPAI-4 (Mayo-Portland
Adaptability Inventory) scores on key measures
 100% of H&C programs received CARF Accreditation
 Satisfaction Scores: 99.1% Very Satisfied / Satisfied
 Strong Key Performance Measures in Creating Jobs:
 Four years of improving performance (84% in Q4)
 95% Customer Satisfaction
 Strong data in Entered Employment, Retained
Employment, Earnings, Attainment of Degree /
Certificate, and Literacy and Numeracy Gains
 Service Delivery (Performance Management) Team
 Leading Manager training program
Behavioral
(1) “NPS” is Net Promoter Score; NPS range is -100 to +100, therefore a “positive” score above 0
is considered “good,” +50 is “excellent,” and above 70 is considered “world class.”
 Industry Leading Investments in Quality and Monitoring
Drive Top Results in Care that Dramatically Reduces Cost:
 4.3 satisfaction / likelihood to recommend (out of 5)
 Behavioral Therapy Satisfaction Scores: 93% Very
Satisfied / Satisfied (90% Very Satisfied); 72% NPS(1)
 35% zero deficiency surveys
 > 50,000 home / site reviews per year
 New Clinical oversight model rolled out in several states
 QuickMar (eMAR) and EHR implementations
 Monitor behavioral incidents: <3% (# of events per qtr /
census), supported by world class de-escalation training
 Implementing new clinical coordination and oversight
w/PREDICS: a proprietary predictive care planning
model
Clients spend an
average of 360
managed days
at home
Hospitalization
rate < 1%
Workforce Services

8. Ensure that Clients are Engaged Daily in the Patient Care Network through a Multitude of Unique Pharmacy Services
Medication Availability
 RxNow
 EMR/EHR Interfaces
 Electronic Prescribing
 Show ‘n Tell
 ViewMasteRx
 TransitionRx
 DischargeRx
 RxSentry
Cost Containment
 PharMerica Formulary
 RxAllow
 RxForecaster; RxExact
 Quantity Limit Program
 Global Authorizations
 Split Billing
 Part D Plan Alerts
 ViewMasteRx
Compliance & Education
 Pharmacist Consulting
 EMR/EHR Interfaces
 RxNow
 EZ-MAR
 Medical Records
 Clinical Focus Areas
 Nurse Consulting Services
 PMC University
 Extensive pharmacy offering and requirements across every client and patient served is a critical link between daily non-
clinical services and periodic clinical services that drives improved outcomes and lower hospitalizations
 Industry leading solutions to ensure accurate and timely access to medications, control pharmacy costs, and support
customer education and remain in compliance with state and federal regulations
Industry Leading Service Metrics Supported by a Unique Set of Value-Add Customer Products that are Differentiated
99.998% Order Accuracy;
99.64% Order Completeness;
97.33% On-Time Delivery;
Comprehensive and Real-Time Reporting
89.59% Generic Dispensing Rate;
Savings Per Rx: $25 on Therapeutic Interchanges,
$22 from Split Billing, $21 from DischargeRx;
$1.06 PPD Quantity Limit Program Savings;
$0.10 Part D/MCD Non-Covered Charges
Implementations Rated 4.8 (out of 5);
Reduced F-Tags (below national average);
Antibiotic Stewardship and Antipsychotic
Reduction clinical programs
BrightSpring-PharMerica has a Leading Pharmacy Platform
that Connects Care Delivery Ecosystem

9. I/DD PHARMACY OVERVIEW
 Pharmacy presence serving the in-home pharmacy needs
of individuals with I/DD and other Behavioral Health /
Mental Health conditions
 Provides services to both affiliate and non-affiliate clients
 Services the majority of BrightSpring’s 24/7 Behavioral
Health population
 Non-affiliate represents greater than 60% of all
persons served
 PharMerica’s national institutional pharmacy platform
creates meaningful growth opportunity by leveraging
BrightSpring’s expertise serving the I/DD population
 Allows for expansion of I/DD pharmacy capabilities
through existing PharMerica footprint
 Significant benefits of scale and COGS-related synergies
easily achievable in I/DD Pharmacy
 Key I/DD Pharmacy Stats
Patients with Three or More
Chronic Conditions57%
Average Number of I/DD
Patient Prescriptions
9
Total I/DD Patients (1)
687K
(2)
1. Represents I/DD patients in Supervised Residential Settings, which is BrightSpring’s expertise
2. Represents incremental $15MM EBITDA opportunity for I/DD pharmacy (represents potential I/DD patient capture by PharMerica pharmacies)

11.  Company has been monitoring and managing the COVID-19 situation daily since February
 New policies, protocols, training, and communications implemented across the enterprise, specific
to COVID-19
 Infection control measures, including limiting and stopping travel early on, shifting to remote work,
and implementing guidelines for meetings
 Dedicated team has worked to procure, distribute and train PPE and related supplies
 Mandated visitor screenings and employee self-screenings and reporting daily
 New tracking tools created
 Management of employee and client/patient at-risk and sick situations, and sick leave and pay
 IT support for tools, enabling remote work, etc.
 Case identification and triage supported by nurse-led quality team
 Quality team led Preparedness and Crisis Plans; Desktop Drills conducted
 Partnered with states on key regulatory and funding considerations
 Four peer-reviewed scientific papers published on our response thus far
OVERVIEW OF COVID-19 RESPONSE

12.  The Committee’s mission is to prepare for potential outbreaks, and to act when necessary to protect, support
and serve our patients, clients and employees, embodying the following guiding principles:
− Preparation
− Reassurance
− Evidence-based Action
− Coordination
− Communication
− Support
 A comprehensive “BrightSpring-PharMerica Enterprise Outbreak Plan” was created and is regularly updated,
August 1, 2020 version available here
OUTBREAK PREPAREDNESS AND ACTION COMMITTEE

13. OUTBREAK COMMITTEE CADENCE
 Daily
− Monitor Johns Hopkins COVID-19 Tracker and CDC and WHO Situation Rooms
− Monitor internally-developed COVID-19 tracking and screening app data
− Communications with Outbreak team and operational leadership
 Weekly
− Executive team live 5pm update and planning
− Company-wide email communications
− Communications with business segment leaders on preparedness and mitigation planning
 Every Other Week
− Full Outbreak Committee meeting
− Update to Executive Committee

14. INTERNALLY DEVELOPED COVID-19 TRACKING & DATA VISUALIZATION APPLICATION
 Each new case entered into the tracker auto triggers response from nursing / quality team who then reaches
out to local operations to coordinate the response (triage, infection control, staffing, PPE plan)

15. INTERNALLY DEVELOPED EMPLOYEE SYMPTOM SCREENING APPLICATION
 Any temperature of 100○
F or higher or a positive symptom screen auto triggers notification of the employee’s
supervisor

16. OVER ONE HUNDRED TWENTY COVID-19 EDUCATIONAL RESOURCES DEVELOPED
 Live infection control sessions open to all employees have been conducted since February

17. NEW PATIENT/CLIENT DAILY CASES OF COVID-19 WITH 5 DAY MOVING AVERAGE
0
2
4
6
8
10
12
14
Number of New Daily Patient or Client Cases
With 5-day Moving Average

18. CUMULATIVE PATIENT & CLIENT CASES OF COVID-19
FIRST CASE THROUGH AUGUST 9, 2020 WITH 30-DAY FORWARD PROJECTION
y = 99775ln(x) - 1E+06
R² = 0.9728
1
10
100
1000
3/17/20
3/24/20
3/31/20
4/7/20
4/14/20
4/21/20
4/28/20
5/5/20
5/12/20
5/19/20
5/26/20
6/2/20
6/9/20
6/16/20
6/23/20
6/30/20
7/7/20
7/14/20
7/21/20
7/28/20
8/4/20
8/11/20
8/18/20
8/25/20
9/1/20
9/8/20

19.  Since the COVID-19 pandemic began in early 2020, BrightSpring-PharMerica has focused
on implementing best practices in infection control, visitor management, employee
screening, and streamlined reporting and triage protocols to optimally support clients,
patients, employees, families and communities.
 To date, we have experienced an overall infection rate of less than one percent
 We have reported our preparation plan, tactics, experience and data in numerous peer-
reviewed research publications (next slide), and the World Health Organization, the
International Long Term Care Network, and the London School for Economics have
included our publication(s) in their policy briefs
SUMMARY OF COVID-19 RESPONSE

20. LEADING THE WAY IN OUTBREAK SUPPRESSION: PUBLISHING OUR
OUTCOMES IN FOUR DIFFERENT SPACES IN LEADING PEER-REVIEWED JOURNALS
Intellectual/Developmental Disability Home Health Care/Personal Home Care
Primary Care and Assisted Living Pharmacy and Long Term Care
* #2 Most Read Article in the Journal in the last 6 mo **Top 5% of all Research Articles EverTracked by Altmetric *

21.  In the 100-day period between 20 January 2020 and 30 April 2020, we provided
continuous support for 11,540 individuals with IDD.
 64% of the individuals were in residential, community settings, and 36% were in
intermediate care facilities.
 The average age of the cohort was 46 ± 12 years, and 60% were male.
 122 individuals with IDD were placed in quarantine for exhibiting symptoms and signs
of acute infection such as fever or cough.
 66 individuals tested positive for SARS-CoV-2, and their average age was 50.
 The positive individuals were located in 30 different homes (1.3% of total) across 14
states.
 15 homes had single cases, and 15 had more than one case.
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH

22. HOW COVID-19 POSITIVE PEOPLE WITH IDD FARED IN THE FIRST 100 DAYS
Strong infection control and outbreak mitigation tactics
have led to low infection, hospitalization and fatality rates

23. GOOD PRESS

24.  Headlands Research, a clinical trial site company that conducts clinical trials at its sites
throughout North America, has been selected for multiple COVID-19 vaccine and treatment
trials, and is offering the opportunity to BrightSpring-PharMerica employees.
 If you qualify to participate, there’s no cost to you. Compensation will be offered to trial
enrollees.
 These vaccines do NOT contain the live virus. Instead, they activate the immune system to
produce antibodies against certain components of the SARS-coV-2 virus.
 Participants must complete follow up (symptom questionnaires, blood tests, etc.), but other than that they
should plan to go about their regular business living their lives. There is NO specific viral challenge in these
studies. People may be exposed or not exposed based in the communities in which they live and through their
regular daily activities. As such, there wouldn’t be any specific or additional risk to our
clients/patients/employees from employee participation.
VOLUNTARY COVID-19 VACCINE TRIAL OPPORTUNITY

25. Outbreak Impacts Expected to Have Longer Term Benefits to BrightSpring-PharMerica
 Interdisciplinary team quickly developed strategy and executed on tactics to suppress virus
transmission
 Intranet education and My Policies built out (over 120 resources)
 Enhanced Enterprise wide-infection control policy, live, cross country education roll out
 Consolidated Crisis Communications
 Tracking of Enterprise-wide average daily census of cases
 Development of a Central Supply function and mass procurement and distribution of scarce PPE
supplies
 Agile, rapid development and launch of three new technologies within four weeks (COVID-19
tracking, Employee Screening app, Enterprise “War Room” Business Intelligence dashboard)
 Enterprise location map
 Development of Point of Care Diagnostic Testing Capabilities
 Telehealth offerings expedited
 Use of Novel Predictive Modeling (community-based thermometers to predict outbreak clusters,
hospital utilization models, etc)
POSITIVE LONG TERM BUSINESS IMPACTS FROM OUTBREAK RESPONSE

27.  Welcome
 Company Overview
 COVID-19 Update
 Q&A
 Summary and Next Steps
John.Mudgett@rescare.com
AGENDA